Skip to Main Content
Home Books Katzung & Trevor's Pharmacology: Examination & Board Review, 11e

Chapter 34: Drugs Used in Coagulation Disorders

INTRODUCTION

The drugs used in clotting and bleeding disorders fall into 2 major groups: (1) drugs used to decrease clotting or dissolve clots already present in patients at risk for vascular occlusion and (2) drugs used to increase clotting in patients with clotting deficiencies. The first group, the anticlotting drugs, includes some of the most commonly used drugs in the United States. Anticlotting drugs are used in the treatment and prevention of myocardial infarction and other acute coronary syndromes, atrial fibrillation, ischemic stroke, and deep vein thrombosis (DVT). Within the anticlotting group, the anticoagulant and thrombolytic drugs are effective in treatment of both venous and arterial thrombosis, whereas antiplatelet drugs are used primarily for treatment of arterial disease.

image

ANTICOAGULANTS

A. Classification

Anticoagulants inhibit the formation of fibrin clots. Three major types of anticoagulants are available: heparin and related products, which must be used parenterally; direct thrombin and factor X inhibitors, which are used parenterally or orally; and the orally active coumarin derivatives (eg, warfarin). Comparative properties of the heparins and warfarin are shown in Table 34–1.

TABLE 34–1Properties of heparins and warfarin.
View Table||Download (.pdf)
TABLE 34–1 Properties of heparins and warfarin.
Property Heparins Warfarin
Structure Large acidic polysaccharide polymers Small lipid-soluble molecule
Route of administration Parenteral Oral
Site of action Blood Liver
Onset of action Rapid (minutes) Slow (days); limited by half-lives of preexisting normal factors
Mechanism of action Activate antithrombin III, which inactivates coagulation factors including thrombin and factor Xa Impairs post-translational modification of factors II, VII, IX and X
Monitoring aPTT for unfractionated heparin but not LMW heparins Prothrombin time
Antidote Protamine for unfractionated heparin; protamine reversal of LMW heparins is incomplete Vitamin K1, plasma, prothrombin complex concentrates
Use Mostly acute, over days Chronic, over weeks to months
Use in pregnancy Yes No

aPTT, activated partial thromboplastin time; LMW, low molecular weight.

B. Heparin

1. Chemistry

Heparin is a large sulfated polysaccharide polymer obtained from animal sources. Each batch contains molecules of varying size, with an average molecular weight of 15,000–20,000. Heparin is highly acidic and can be neutralized by basic molecules (eg, protamine). Heparin is given intravenously or subcutaneously to avoid the risk of hematoma associated with intramuscular injection.

Low-molecular-weight (LMW) fractions of heparin (eg, enoxaparin) have molecular weights of 2000–6000. LMW heparins have greater bioavailability and longer durations of action than unfractionated heparin; thus, doses can be given less frequently (eg, once or twice a day). They are given subcutaneously. Fondaparinux is a small synthetic drug that contains the biologically active pentasaccharide present in unfractionated and LMW heparins. It is administered subcutaneously once daily.

| Download (.pdf) | Print
High-Yield Terms to Learn
Activated partial thromboplastin ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close